UNITY Biotechnology IncNASDAQ:UBX
- LAST PRICE1.4800
- TODAY'S CHANGE (%)0.0100 (0.6803%)
- Bid / Lots1.4800/ 75
- Ask / Lots1.5600/ 52
- Open / Previous Close1.4800 / 1.4700
- Day Range
- 52 Week Range
- Volume53,840
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | UBX |
|---|---|---|
| 09:32 ET | 1171 | 1.48 |
| 09:36 ET | 225 | 1.5 |
| 09:38 ET | 1547 | 1.49 |
| 09:41 ET | 106 | 1.4901 |
| 09:48 ET | 100 | 1.51 |
| 09:50 ET | 2443 | 1.5 |
| 10:03 ET | 350 | 1.5 |
| 10:06 ET | 500 | 1.5001 |
| 10:08 ET | 110 | 1.505 |
| 10:12 ET | 1500 | 1.505 |
| 10:15 ET | 664 | 1.509 |
| 10:19 ET | 2000 | 1.5035 |
| 10:21 ET | 100 | 1.505 |
| 10:24 ET | 805 | 1.52 |
| 10:30 ET | 1000 | 1.51 |
| 10:39 ET | 200 | 1.505 |
| 10:42 ET | 792 | 1.51 |
| 10:50 ET | 400 | 1.52 |
| 10:55 ET | 500 | 1.5001 |
| 11:13 ET | 500 | 1.5069 |
| 11:18 ET | 2200 | 1.5 |
| 11:33 ET | 300 | 1.505 |
| 11:42 ET | 254 | 1.4954 |
| 11:54 ET | 775 | 1.5 |
| 11:58 ET | 100 | 1.52 |
| 12:03 ET | 150 | 1.505 |
| 12:14 ET | 191 | 1.5 |
| 12:20 ET | 400 | 1.4847 |
| 12:25 ET | 200 | 1.5 |
| 12:27 ET | 5153 | 1.48 |
| 12:30 ET | 300 | 1.49 |
| 12:32 ET | 500 | 1.49 |
| 12:41 ET | 150 | 1.49 |
| 12:43 ET | 200 | 1.4992 |
| 12:45 ET | 500 | 1.49 |
| 01:03 ET | 339 | 1.4917 |
| 01:08 ET | 100 | 1.5 |
| 01:15 ET | 416 | 1.49 |
| 01:17 ET | 200 | 1.49 |
| 01:33 ET | 300 | 1.49 |
| 01:35 ET | 497 | 1.4817 |
| 01:42 ET | 785 | 1.49 |
| 01:53 ET | 100 | 1.48 |
| 01:57 ET | 100 | 1.49 |
| 02:18 ET | 400 | 1.485 |
| 02:29 ET | 674 | 1.4894 |
| 02:56 ET | 193 | 1.49 |
| 03:05 ET | 178 | 1.4891 |
| 03:30 ET | 426 | 1.4858 |
| 03:36 ET | 143 | 1.489 |
| 03:43 ET | 891 | 1.4899 |
| 03:48 ET | 768 | 1.48 |
| 03:54 ET | 13774 | 1.48 |
| 03:56 ET | 300 | 1.48 |
| 03:57 ET | 300 | 1.48 |
| 03:59 ET | 1288 | 1.48 |
May 15, 2024
DJ Unity Biotechnology Price Target Maintained With a $8.00/Share by HC Wainwright & Co., from 11:17AM ET on Wednesday May 15, 2024 by Dow Jones
11:17AM ET on Wednesday May 15, 2024 by Dow Jones
May 14, 2024
*DJ Unity Biotechnology 1Q Loss/Shr 34c >UBX, from 5:00PM ET on Tuesday May 14, 2024 by Dow Jones
5:00PM ET on Tuesday May 14, 2024 by Dow JonesUNITY Biotechnology, Inc. Reports First Quarter 2024 Financial Results and Business Updates, from 5:00PM ET on Tuesday May 14, 2024 by Dow Jones
5:00PM ET on Tuesday May 14, 2024 by Dow Jones
Apr 25, 2024
UNITY Biotechnology Announces Upcoming Presentations at the ARVO 2024 Annual Meeting, from 8:00AM ET on Thursday Apr 25, 2024 by Dow Jones
8:00AM ET on Thursday Apr 25, 2024 by Dow Jones
Apr 23, 2024
UNITY Biotechnology Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME, from 8:00AM ET on Tuesday Apr 23, 2024 by Dow Jones
8:00AM ET on Tuesday Apr 23, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
UNITY Biotechnology Inc | 24.8M | -0.6x | --- |
NKGen Biotech Inc | 25.2M | -0.3x | --- |
NanoViricides Inc | 24.4M | -2.6x | --- |
Biora Therapeutics Inc | 26.2M | -0.1x | --- |
Iterum Therapeutics PLC | 23.3M | -0.5x | --- |
Enlivex Therapeutics Ltd | 26.5M | -0.9x | --- |
Company Information
Unity Biotechnology, Inc. is a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging. The Company is focused on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. It is targeting specific biological mechanisms implicated in diseases of aging. Its core therapeutic approach targets cellular senescence and is advancing senolytic programs primarily in ophthalmologic disorders. In addition, it has other programs based on other biologies of aging to include an agonistic antibody to the Tie2 receptor and a Tie2/VEGF bispecific to treat vascular eye disease. UBX1325 is its advanced lead drug candidate for age-related diseases of the eye, including diabetic macular edema. UBX1967 is its back-up compound to UBX1325. UBX2089, an α-Klotho hormone drug candidate, which is being researched for multiple neurology indications.
Contact Information
- Headquarters
- 285 EAST GRAND AVENUESOUTH SAN FRANCISCO, CA, United States 94080
- Phone
- 650-416-1192
- Fax
- 302-655-5049
Executives
- Chairman of the Board
- Keith Leonard
- Chief Executive Officer, Director
- Anirvan Ghosh
- Chief Financial Officer, Head of Corporate Development
- Lynne Sullivan
- General Counsel and Corporate Secretary
- Alexander Nguyen
- Lead Independent Director
- Paul Berns
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $24.8M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 16.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.89 |
EPS | $-2.33 |
Book Value | $1.69 |
P/E Ratio | -0.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
